These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23479212)

  • 1. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.
    Bechmann T; Andersen RF; Pallisgaard N; Madsen JS; Maae E; Jakobsen EH; Bak Jylling AM; Steffensen KD; Jakobsen A
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):995-1003. PubMed ID: 23479212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of HER2 amplification in circulating free DNA in patients with breast cancer.
    Page K; Hava N; Ward B; Brown J; Guttery DS; Ruangpratheep C; Blighe K; Sharma A; Walker RA; Coombes RC; Shaw JA
    Br J Cancer; 2011 Apr; 104(8):1342-8. PubMed ID: 21427727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.
    Shoda K; Masuda K; Ichikawa D; Arita T; Miyakami Y; Watanabe M; Konishi H; Imoto I; Otsuji E
    Gastric Cancer; 2015 Oct; 18(4):698-710. PubMed ID: 25322965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
    Antolín S; García-Caballero L; Reboredo C; Molina A; Mosquera J; Vázquez-Boquete Á; Gallego R; Santiago MP; Concha Á; Pérez E; Calvo L; García-Caballero T
    Virchows Arch; 2021 Oct; 479(4):853-857. PubMed ID: 33934230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Wang RX; Chen S; Jin X; Chen CM; Shao ZM
    Breast Cancer Res Treat; 2017 Jan; 161(2):259-267. PubMed ID: 27885439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
    Rakha EA; Miligy IM; Quinn CM; Provenzano E; Shaaban AM; Marchiò C; Toss MS; Gallagy G; Murray C; Walshe J; Katayama A; Eldib K; Badr N; Tanchel B; Millican-Slater R; Purdie C; Purnell D; Pinder SE; Ellis IO; Lee AHS
    Br J Cancer; 2021 May; 124(11):1836-1842. PubMed ID: 33762723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.
    Page K; Guttery DS; Fernandez-Garcia D; Hills A; Hastings RK; Luo J; Goddard K; Shahin V; Woodley-Barker L; Rosales BM; Coombes RC; Stebbing J; Shaw JA
    Clin Chem; 2017 Feb; 63(2):532-541. PubMed ID: 27940449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies.
    de Cremoux P; Martin EC; Vincent-Salomon A; Dieras V; Barbaroux C; Liva S; Pouillart P; Sastre-Garau X; Magdelenat H
    Int J Cancer; 1999 Oct; 83(2):157-61. PubMed ID: 10471520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
    Breast Cancer Res Treat; 2020 Apr; 180(2):321-329. PubMed ID: 32002765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.